AG百家乐代理-红桃KAG百家乐娱乐城

Research News

Nature Reviews Drug Discovery: targeting cancer-associated fibroblasts

Share
  • Updated: Dec 24, 2018
  • Written:
  • Edited:
Source: Sun Yat-sen Memorial Hospital
Written by: Xueman Chen
Edited by: Wang Dongmei

Recently, a Review Article entitled “Turning foes to friends: targeting cancer-associated fibroblasts” was published online in Nature Reviews Drug Discovery (IF 2018=50.17)1. Professor Erwei Song, President of Sun Yat-sen Memorial Hospital, Sun Yat-sen University, is the corresponding author, and Xueman Chen, a PhD student from his team, is the first author.

Current paradigms of cancer-centric therapeutics are usually not sufficient to eradicate the malignancy, as the cancer stroma may prompt tumor relapse and therapeutic resistance. In the past decade, a burst of knowledge on how the tumor microenvironment (TME) interacts with tumor cells has urged studies on a new cancer treatment paradigm: targeting the tumor stroma. Among all the stromal cells that populate the TME, cancer-associated fibroblasts (CAFs) are the most abundant and are critically involved in cancer progression, which render them as conspicuous stromal targets in many, if not all, solid tumors. However, without unequivocal cell-surface markers, live-cell sorting for functional and mechanistic studies on CAFs in vitro and targeting therapies towards CAFs in vivo are greatly hindered.

It is noteworthy that a previous research from Prof. Erwei Song’s team revealed CD10 and GPR77 as two specific cell-surface makers for a novel pro-tumorigenic CAF subset involved in cancer stemness and chemoresistance2. More importantly, GPR77 is a functional marker which can be directly targeted for in vivo CAF depletion. The restoration of chemosensitivity of tumor cells upon GPR77 blockade further suggests the remarkable therapeutic value of such a precise CAF-targeted strategy for cancers.


Accumulated molecular characterization of CAFs not only deepens our insights into their phenotypic heterogeneity and functional diversity, but also brings CAF-targeting therapies for cancer treatment onto the agenda. However, translating the basic research into clinical practice takes tremendous efforts and is extremely time-consuming, which makes it an urgent need for therapists and drug developers to comprehensively recognize the functional significance and molecular mechanisms of CAFs in cancers.

In this Review, Prof. Song’s team presented a full-scale overview regarding the current understanding of the hallmarks, biology and heterogeneity of CAFs, highlighting the CAF-centered intercellular crosstalk within the TME, and discussed multipronged functions of CAFs in tumor initiation, progression, metastasis and resistance to anticancer therapies. Prof. Song’s team also elaborated on the potential therapeutic strategies targeting CAFs, with an aim to accelerate the leap from bench to bedside.


References
1.  Chen, X. & Song, E. Turning foes to friends: targeting cancer-associated fibroblasts. Nature Reviews Drug Discovery (2018).
2.  Su, S., et al. CD10(+)GPR77(+) Cancer-Associated Fibroblasts Promote Cancer Formation and Chemoresistance by Sustaining Cancer Stemness. Cell (2018).

Link to the review article: www.nature.com/articles/s41573-018-0004-1
TOP
百家乐官网有没有稳赢| 百家乐官网透视牌靴价格| 抚宁县| 手机百家乐的玩法技巧和规则 | 百家乐官网稳赢投注| 线上百家乐| 游戏机百家乐官网的技巧| 赌场游戏| 大发888注册58| 上海百家乐赌博| 百家乐官网微笑打法| 百家乐官网必胜下注法| 微信百家乐群规则大全| 百家乐分析软件下| 真人百家乐官网攻略| 百家乐官网能战胜吗| 三公百家乐官网玩法| 铜川市| 大发888网站大全| 电脑百家乐玩| 百家乐怎么玩了| 如何赢百家乐官网的玩法技巧和规则| 百家乐官网稳赢赌法| 澳门娱乐城开户| 大发888客户端| 宝龙百家乐的玩法技巧和规则| 属羊的和属猪的做生意| 基础百家乐官网的玩法技巧和规则 | 大发888微信公众号2| 大发888娱乐城新澳博| 91百家乐的玩法技巧和规则| 百家乐单机版的| 职业赌百家乐技巧| 真钱百家乐注册送| 百家乐太阳城球讯网| 太阳城百家乐主页| 百家乐定位膽技巧| 真人百家乐破解软件下载| 百家乐庄闲和赢率| 百家乐便利| 不夜城百家乐的玩法技巧和规则 |